Opaleye Management’s Intellia Therapeutics NTLA Stock Holding History

Opaleye Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.23M	Buy	250,000 +5,000	+2%	+$70K	0.38%	38
2026 Q1	$3.14M	Buy	+245,000	New	+$3.12M	0.41%	41
2024 Q3	–	Sell	-218,000	Closed	-$4.88M	–	52
2024 Q2	$4.88M	Sell	218,000 -37,000	-15%	-$881K	1.11%	27
2024 Q1	$7.02M	Buy	255,000 +156,000	+158%	+$4.33M	1.53%	22
2023 Q4	$3.02M	Buy	+99,000	New	+$2.85M	0.8%	29
2023 Q3	–	Sell	-120,000	Closed	-$4.89M	–	48
2023 Q2	$4.89M	Buy	+120,000	New	+$4.87M	1.17%	23

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Opaleye Management's NTLA Position: Q2 2026 in Review

Opaleye Management increased its Intellia Therapeutics (NTLA) stake by 2% in Q2 2026, buying an estimated $70K and bringing the position to 250,000 shares worth $4.23M. The position accounts for 0.38% of the portfolio, ranked #38.

Opaleye Management first reported a position in NTLA in Q2 2023 and has held it in 6 quarters since. The position peaked at $7.02M in Q1 2024. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Opaleye Management held 250,000 shares of Intellia Therapeutics worth $4.23M as of Q2 2026.
Opaleye Management bought 5,000 Intellia Therapeutics shares in Q2 2026, an estimated $70K.
Intellia Therapeutics made up 0.38% of Opaleye Management's portfolio in Q2 2026, its #38 holding.
Opaleye Management first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 6 quarters since.
Opaleye Management's Intellia Therapeutics position peaked at $7.02M in Q1 2024.
327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.